Answers are grounded in this paper and cite their sources.
Blood disorders and the immune system share a complex and dynamic relationship, influencing disease susceptibility, progression, and treatment outcomes. Hematological abnormalities, including anemia, leukemias, and clotting disorders, can disrupt immune homeostasis, increasing vulnerability to infections, autoimmune conditions, and malignancies. Conversely, immune dysregulation plays a crucial role in the development and exacerbation of various blood disorders, as seen in immune-mediated hemolytic anemia, aplastic anemia, and hematological malignancies such as lymphomas and leukemias. The intricate cross-talk between hematopoiesis and immune function is mediated by cytokines, inflammatory signaling pathways, and bone marrow microenvironmental changes. These interactions can either promote disease pathogenesis or offer potential therapeutic targets. Advances in immunotherapy, bone marrow transplantation, and targeted molecular therapies underscore the importance of understanding these connections for improving clinical management. This review provides a comprehensive overview of the bidirectional relationship between blood disorders and immunity, discussing key mechanisms, clinical implications, and emerging therapeutic strategies. By elucidating these interactions, we aim to enhance current treatment approaches and contribute to the development of novel immunomodulatory interventions that optimize patient outcomes.
No takes yet. Share an insight, caveat, or question.
Nakaziya Obutuzi G. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: